Recruitment Restarts in Pancreatic Cancer Trial

Release Highlights:

• Recruitment of the final cohort of patients in the ACCENT clinical trial has begun with the first patient having started on trial this week.
• The final cohort of 24 patients adds to the 26 patients already enrolled on the trial
• The ACCENT trial explores the activity of narmafotinib, in combination with standard-of-care chemotherapy, in advanced pancreatic cancer patients